Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol

Current Atherosclerosis Reports

Volumn 12, Issue 5, 2010, Pages 301-307

  Nicholls, Stephen J ^a   Uno, Kiyoko ^a   Tuzcu, E Murat ^a   Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; HDL; Imaging; Intravascular ultrasound; Risk factors

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ETC 216; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PIOGLITAZONE; PLACEBO; RIMONABANT; SIBUTRAMINE; TORCETRAPIB;

ABDOMINAL OBESITY; ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EXERCISE; HUMAN; INTRAVASCULAR ULTRASOUND; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REMISSION; REVIEW; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; CORONARY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; HUMANS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77956267324     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0125-4     Document Type: Review

References (63)

1. D Lloyd-Jones R Adams M Carnethon, et al. 2009 Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 e21 181 10.1161/CIRCULATIONAHA.108.191261 19075105
2. C Baigent A Keech PM Kearney, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins Lancet 366 1267 1278 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM 16214597
3. B Neal S MacMahon N Chapman 2000 Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 1955 1964 10.1016/S0140-6736(00)03307-9 1:STN:280:DC%2BD3M%2FnvFaitA%3D%3D 11130523
4. DJ Gordon JL Probstfield RJ Garrison, et al. 1989 High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 8 15 1:STN:280:DyaL1M%2FptVWjtg%3D%3D 2642759
5. DJ Gordon BM Rifkind 1989 High-density lipoprotein-the clinical implications of recent studies N Engl J Med 321 1311 1316 1:STN:280: DyaK3c%2FhsFSmsA%3D%3D 2677733
6. T Gordon WP Castelli MC Hjortland, et al. 1977 High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 707 714 10.1016/0002-9343(77)90874-9 1:CAS:528:DyaE2sXhvVOhtbg%3D 193398
7. P Barter AM Gotto JC LaRosa, et al. 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310 10.1056/NEJMoa064278 1:CAS:528:DC%2BD2sXhtFSmtr3M 17898099
8. PW Wilson RB D'Agostino D Levy, et al. 1998 Prediction of coronary heart disease using risk factor categories Circulation 97 1837 1847 1:STN:280:DyaK1c3msVOjsA%3D%3D 9603539
9. JJ Badimon L Badimon A Galvez, et al. 1989 High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits Lab Invest 60 455 461 1:CAS:528:DyaL1MXhvFShurk%3D 2927083
10. JJ Badimon L Badimon V Fuster 1990 Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1234 1241 10.1172/JCI114558 1:CAS:528:DyaK3cXitlehtbw%3D 2318976
11. SJ Nicholls B Cutri SG Worthley, et al. 2005 Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits Arterioscler Thromb Vasc Biol 25 2416 2421 10.1161/01.ATV.0000184760. 95957.d6 1:CAS:528:DC%2BD2MXhtFCisbbK 16141405
12. AS Plump CJ Scott JL Breslow 1994 Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci U S A 91 9607 9611 10.1073/pnas.91.20.9607 1:CAS:528:DyaK2cXmt1Okur0%3D 7937814
13. EM Rubin RM Krauss EA Spangler, et al. 1991 Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI Nature 353 265 267 10.1038/353265a0 1:CAS:528:DyaK3MXmtVKrsL0%3D 1910153
14. JX Rong J Li ED Reis, et al. 2001 Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content Circulation 104 2447 2452 10.1161/hc4501.098952 1:CAS:528:DC%2BD3MXpt1KhsL8%3D 11705823
15. PK Shah J Yano O Reyes, et al. 2001 High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization Circulation 103 3047 3050 10.1161/hc2501.092494 1:CAS:528:DC%2BD3MXlsFyhsLs%3D 11425766
16. VI Zannis A Chroni M Krieger 2006 Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL J Mol Med (Berlin) 84 276 294 1:CAS:528: DC%2BD28XjtVSmsL4%3D
17. PJ Barter S Nicholls KA Rye, et al. 2004 Antiinflammatory properties of HDL Circ Res 95 764 772 10.1161/01.RES.0000146094.59640.13 1:CAS:528: DC%2BD2cXot1aitrY%3D 15486323
18. AC van der Wal AE Becker CM van der Loos PK Das 1994 Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology Circulation 89 36 44 8281670
19. D Waters TE Craven J Lesperance 1993 Prognostic significance of progression of coronary atherosclerosis Circulation 87 1067 1075 1:STN:280:DyaK3s3hsFSntw%3D%3D 8484829
20. EM Tuzcu P Schoenhagen 2004 Atherosclerosis imaging: intravascular ultrasound Drugs 64 Suppl 2 1 7 10.2165/00003495-200464002-00002 15765887
21. GS Mintz SE Nissen WD Anderson, et al. 2001 American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 37 1478 1492 10.1016/S0735-1097(01)01175-5 1:STN:280:DC%2BD3M3gvFKgsg%3D%3D 11300468
22. SE Nissen EM Tuzcu P Schoenhagen, et al. 2005 Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 29 38 10.1056/NEJMoa042000 1:CAS:528:DC%2BD2MXis12msQ%3D%3D 15635110
23. Third Report of the National Cholesterol Education Program (NCEP) 2002 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 3143 3421
24. SE Nissen SJ Nicholls I Sipahi, et al. 2006 Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 1556 1565 10.1001/jama.295.13.jpc60002 1:CAS:528:DC%2BD28Xjt12itrc%3D 16533939
25. SJ Nicholls EM Tuzcu I Sipahi, et al. 2007 Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 499 508 10.1001/jama.297.5.499 1:CAS:528:DC%2BD2sXhs1Wis7k%3D 17284700
26. SE Nissen T Tsunoda EM Tuzcu, et al. 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2292 2300 10.1001/jama.290.17.2292 1:CAS:528:DC%2BD3sXovVCjtbc%3D 14600188
27. SJ Nicholls EM Tuzcu I Sipahi, et al. 2006 Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano J Am Coll Cardiol 47 992 997 10.1016/j.jacc.2005.11.040 1:CAS:528: DC%2BD28XitVaruro%3D 16516083
28. JC Tardif J Gregoire PL L'Allier, et al. 2007 Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 1675 1682 10.1001/jama.297.15.jpc70004 17387133
29. RK Waksman A Pichard 2008 A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high density lipoprotein plasma infusions in patients with acute coronary syndrome Circulation 118 S-371 abstract 1697
30. FM Sacks LL Rudel A Conner, et al. 2009 Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 894 907 10.1194/jlr.M800622-JLR200 1:CAS:528:DC%2BD1MXkvVSnu7k%3D 19144994
31. SM Boekholdt JA Kuivenhoven NJ Wareham, et al. 2004 Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study Circulation 110 1418 1423 10.1161/01.CIR.0000141730.65972.95 1:CAS:528:DC%2BD2cXnt12isr0%3D 15337694
32. LA Morehouse ED Sugarman PA Bourassa, et al. 2007 Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J Lipid Res 48 1263 1272 10.1194/jlr.M600332-JLR200 1:CAS:528:DC%2BD2sXmtFGmt7w%3D 17325387
33. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL 17984165
34. SE Nissen JC Tardif SJ Nicholls, et al. 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316 10.1056/NEJMoa070635 1:CAS:528:DC%2BD2sXjsFGnsrY%3D 17387129
35. ML Bots FL Visseren GW Evans, et al. 2007 Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 153 160 10.1016/S0140-6736(07)61088-5 1:CAS:528:DC%2BD2sXns12jtLg%3D 17630038
36. SJ Nicholls EM Tuzcu DM Brennan, et al. 2008 Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation 118 2506 2514 10.1161/CIRCULATIONAHA.108.790733 1:CAS:528:DC%2BD1cXhsVerur3L 19029466
37. M Vergeer ML Bots SI van Leuven, et al. 2008 Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2515 2522 10.1161/CIRCULATIONAHA.108.772665 1:CAS:528:DC%2BD1cXhsVerur3K 19029469
38. WP James A Astrup N Finer, et al. 2000 Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance Lancet 356 2119 2125 10.1016/S0140-6736(00)03491-7 1:CAS:528:DC%2BD3MXitlGhtQ%3D%3D 11191537
39. AM Dattilo PM Kris-Etherton 1992 Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis Am J Clin Nutr 56 320 328 1:CAS:528:DyaK38XlslSju7Y%3D 1386186
40. SE Nissen SJ Nicholls K Wolski, et al. 2008 Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial JAMA 299 1547 1560 10.1001/jama.299.13.1547 1:CAS:528:DC%2BD1cXktlSlurY%3D 18387931
41. SJ Nicholls A Hsu K Wolski, et al. 2009 Baseline lipid levels and progression of coronary atherosclerosis in abdominally obese patients J Am Coll Cardiol 53 A200 10.1016/j.jacc.2008.09.033
42. AJ Taylor LE Sullenberger HJ Lee, et al. 2004 Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 3512 3517 10.1161/01.CIR.0000148955.19792.8D 1:CAS:528:DC%2BD2MXhtVGnt7s%3D 15537681
43. AJ Taylor HJ Lee LE Sullenberger 2006 The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2243 2250 10.1185/030079906X148508 1:CAS:528:DC%2BD28XhtlCku7jK 17076985
44. MH Frick O Elo K Haapa, et al. 1987 Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1237 1245 1:STN:280:DyaL1c%2FjvFSjtw%3D%3D 3313041
45. HB Rubins SJ Robins D Collins, et al. 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 410 418 10.1056/ NEJM199908053410604 1:CAS:528:DyaK1MXltlyltbw%3D 10438259
46. RS Elkeles JR Diamond C Poulter, et al. 1998 Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care 21 641 648 10.2337/diacare.21.4.641 1:STN:280:DyaK1c3jt1ynug%3D%3D 9571357
47. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
48. SE Nissen SJ Nicholls K Wolski, et al. 2008 Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 1561 1573 10.1001/jama.299.13.1561 1:CAS:528:DC%2BD1cXktlSqtbg%3D 18378631
49. SJ Nicholls T Hu S Kupfer, et al. 2008 Lowering of the triglyceride/HDL cholesterol ratio predicts the benefit of pioglitazone on progression of coronary atherosclerosis in diabetic patients Circulation 118 S-1135 10.1161/CIRCULATIONAHA.108.790733
50. T Mazzone PM Meyer SB Feinstein, et al. 2006 Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2572 2581 10.1001/jama.296.21.joc60158 1:CAS:528:DC%2BD28Xht12lsbbM 17101640
51. M Davidson PM Meyer S Haffner, et al. 2008 Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus Circulation 117 2123 2130 10.1161/CIRCULATIONAHA.107.746610 1:CAS:528: DC%2BD1cXks1Gjsb4%3D 18413496
52. AC King WL Haskell DR Young, et al. 1995 Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years Circulation 91 2596 2604 1:CAS:528:DyaK2MXms12nsr4%3D 7743622
53. AS Leon J Connett DR Jacobs Jr R Rauramaa 1987 Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial JAMA 258 2388 2395 10.1001/jama.258.17.2388 1:STN:280:DyaL1c%2Fjs1ehtg%3D%3D 3669210
54. SN Blair HW Kohl 3rd RS Paffenbarger Jr, et al. 1989 Physical fitness and all-cause mortality. A prospective study of healthy men and women JAMA 262 2395 2401 10.1001/jama.262.17.2395 1:STN:280:DyaK3c%2Fht1Giug%3D%3D 2795824
55. K Maeda Y Noguchi T Fukui 2003 The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis Prev Med 37 283 290 10.1016/S0091-7435(03)00110-5 1:CAS:528:DC%2BD3sXnsVWruro%3D 14507483
56. K Meksawan DR Pendergast JJ Leddy, et al. 2004 Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women J Am Coll Nutr 23 131 140 15047679
57. AH Lichtenstein 2003 Dietary fat and cardiovascular disease risk: quantity or quality? J Women Health 12 109 114 10.1089/154099903321576493
58. S Tani K Nagao T Anazawa, et al. 2010 Coronary plaque regression and lifestyle modification in patients treated with pravastatin. Assessment mainly by daily aerobic exercise and an increase in the serum level of high-density lipoprotein cholesterol Circ J 74 954 961 10.1253/circj.CJ-09-0705 1:CAS:528:DC%2BC3cXms1ajtr8%3D 20234098
59. LT Bloedon R Dunbar D Duffy, et al. 2008 Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients J Lipid Res 49 1344 1352 10.1194/jlr.P800003-JLR200 1:CAS:528:DC%2BD1cXmslWnu7w%3D 18323573
60. SB Joseph E McKilligin L Pei, et al. 2002 Synthetic LXR ligand inhibits the development of atherosclerosis in mice Proc Natl Acad Sci U S A 99 7604 7609 10.1073/pnas.112059299 1:CAS:528:DC%2BD38XktlCrsr8%3D 12032330
61. AS deLemos ML Wolfe CJ Long, et al. 2002 Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol Circulation 106 1321 1326 10.1161/01.CIR.0000028423.07623.6A 1:CAS:528:DC%2BD38XntVKks7k%3D 12221047
62. SJ Nicholls 2008 HDL: still a target for new therapies? Curr Opin Investig Drugs 9 950 956 1:CAS:528:DC%2BD1cXhtFKntr7M 18729001
63. A Nair BD Kuban EM Tuzcu, et al. 2002 Coronary plaque classification with intravascular ultrasound radiofrequency data analysis Circulation 106 2200 2206 10.1161/01.CIR.0000035654.18341.5E 12390948